Tags

Type your tag names separated by a space and hit enter

Audio Interview: Tocilizumab and Covid-19.
N Engl J Med. 2020 Oct 22; 383(17):e114.NEJM

Links

Publisher Full Text (DOI)

Authors

Rubin EJ
No affiliation info available
Baden LR
No affiliation info available
Morrissey S
No affiliation info available

MeSH

Anti-Inflammatory AgentsAntibodies, Monoclonal, HumanizedBetacoronavirusCOVID-19Confidence IntervalsCoronavirus InfectionsDexamethasoneGlucocorticoidsHumansInflammationInterleukin-6PandemicsPneumonia, ViralRespiratory Distress SyndromeSARS-CoV-2Treatment FailureVirus ReplicationCOVID-19 Drug Treatment

Pub Type(s)

Editorial

Language

eng

PubMed ID

33085870

Citation

Rubin, Eric J., et al. "Audio Interview: Tocilizumab and Covid-19." The New England Journal of Medicine, vol. 383, no. 17, 2020, pp. e114.
Rubin EJ, Baden LR, Morrissey S. Audio Interview: Tocilizumab and Covid-19. N Engl J Med. 2020;383(17):e114.
Rubin, E. J., Baden, L. R., & Morrissey, S. (2020). Audio Interview: Tocilizumab and Covid-19. The New England Journal of Medicine, 383(17), e114. https://doi.org/10.1056/NEJMe2032051
Rubin EJ, Baden LR, Morrissey S. Audio Interview: Tocilizumab and Covid-19. N Engl J Med. 2020 Oct 22;383(17):e114. PubMed PMID: 33085870.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Audio Interview: Tocilizumab and Covid-19. AU - Rubin,Eric J, AU - Baden,Lindsey R, AU - Morrissey,Stephen, PY - 2020/10/21/entrez PY - 2020/10/22/pubmed PY - 2020/11/4/medline SP - e114 EP - e114 JF - The New England journal of medicine JO - N Engl J Med VL - 383 IS - 17 SN - 1533-4406 UR - https://www.unboundmedicine.com/medline/citation/33085870/Audio_Interview:_Tocilizumab_and_Covid_19_ DB - PRIME DP - Unbound Medicine ER -